CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: August 10, 2020
Result type: Reports
Project Number: SR0653-000
Product Line: Common Drug Review

Generic Name: Levetiracetam

Brand Name: pdp-levETIRAcetam

Manufacturer: Pendopharm, a division of Pharmascience Inc.

Indications: Epilepsy

Manufacturer Requested Reimbursement Criteria1: For patients on levetiracetam that cannot intake solid oral tablets.

Submission Type: New

Project Status: Active

Companion Diagnostics: No

Fee Schedule: Schedule C

  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient input openJune 17, 2020
Call for patient input closedAugust 07, 2020

- No patient input submission received

Submission receivedJuly 17, 2020
Submission acceptedAugust 05, 2020

- Submission was not accepted for review on 31 Jul 2020

- Revised category 1 requirements received on 31 Jul 2020

Review initiatedAugust 06, 2020
Draft CADTH review report(s) provided to sponsor for commentOctober 21, 2020
Deadline for sponsors commentsOctober 30, 2020
CADTH responses on draft review report(s) provided to sponsorNovember 27, 2020
Expert committee meeting (initial)December 09, 2020
Draft recommendation issuedDecember 21, 2020
December 23, 2020